365 related articles for article (PubMed ID: 7888199)
1. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration.
Lubeck MD; Natuk RJ; Chengalvala M; Chanda PK; Murthy KK; Murthy S; Mizutani S; Lee SG; Wade MS; Bhat BM
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1443-9. PubMed ID: 7888199
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees.
Natuk RJ; Lubeck MD; Chanda PK; Chengalvala M; Wade MS; Murthy SC; Wilhelm J; Vernon SK; Dheer SK; Mizutani S
AIDS Res Hum Retroviruses; 1993 May; 9(5):395-404. PubMed ID: 8318268
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus vectored vaccines.
Natuk RJ; Davis AR; Chanda PK; Lubeck MD; Chengalvala M; Murthy SC; Wade MS; Dheer SK; Bhat BM; Murthy KK
Dev Biol Stand; 1994; 82():71-7. PubMed ID: 7958485
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.
Natuk RJ; Chanda PK; Lubeck MD; Davis AR; Wilhelm J; Hjorth R; Wade MS; Bhat BM; Mizutani S; Lee S
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7777-81. PubMed ID: 1502197
[TBL] [Abstract][Full Text] [Related]
5. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
6. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
[TBL] [Abstract][Full Text] [Related]
7. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Kliks S; Wright PF
J Clin Immunol; 1992 Nov; 12(6):429-39. PubMed ID: 1287035
[TBL] [Abstract][Full Text] [Related]
8. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
9. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
10. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
11. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
Akerblom L; Nara P; Dunlop N; Putney S; Morein B
Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
[TBL] [Abstract][Full Text] [Related]
12. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
13. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
Barrett N; Eder G; Dorner F
Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
[TBL] [Abstract][Full Text] [Related]
16. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
17. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
Parry C; McLain L; Dimmock NJ
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.
Hu SL; Klaniecki J; Dykers T; Sridhar P; Travis BM
AIDS Res Hum Retroviruses; 1991 Jul; 7(7):615-20. PubMed ID: 1768463
[TBL] [Abstract][Full Text] [Related]
19. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine.
Fuller DH; Haynes JR
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1433-41. PubMed ID: 7888198
[TBL] [Abstract][Full Text] [Related]
20. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
